本页面由Tiger Trade Technology Pte. Ltd.提供服务

Harmony Biosciences Holdings, Inc.

38.50
+0.35000.92%
盘前38.500.00000.00%07:00 EDT
成交量:48.61万
成交额:1,870.98万
市值:22.42亿
市盈率:12.46
高:38.93
开:38.13
低:37.48
收:38.15
52周最高:40.87
52周最低:25.52
股本:5,823.64万
流通股本:5,080.33万
量比:0.80
换手率:0.96%
股息:- -
股息率:- -
每股收益(TTM):3.09
每股收益(LYR):2.71
净资产收益率:20.46%
总资产收益率:11.62%
市净率:2.24
市盈率(LYR):14.21

数据加载中...

公司资料

公司名字:
Harmony Biosciences Holdings, Inc.
交易所:
NASDAQ
成立时间:
2017
员工人数:
293
公司地址:
630 West Germantown Pike,Suite 215,Plymouth Meeting,Pennsylvania,United States
邮编:
19462
电话:
传真:
- -
简介:
Harmony Biosciences Holdings, Inc.于2017年7月25日成立,是一家商业阶段的制药公司,致力于为患有罕见的神经系统疾病且未满足医疗需求的患者开发和商业化创新疗法。该公司的产品WAKIX(pitolisant)是具有新颖作用机制或MOA的一流分子,专门设计用于通过与H3受体结合来增强大脑中的组胺信号传导。

董事

名称
职位
Jeffrey M. Dayno
Chief Executive Officer,Director and President
Jeffrey S. Aronin
Chairman and Director
Andreas Wicki
Independent Director
Antonio Gracias
Independent Director
Gary Sender
Independent Director
Juan A. Sabater
Independent Director
Linda Szyper
Independent Director
R. Mark Graf
Independent Director
Ron Philip
Independent Director
Troy Ignelzi
Independent Director

股东

名称
职位
Jeffrey M. Dayno
Chief Executive Officer,Director and President
Peter Anastasiou
Chief Operating Officer
Sandip Kapadia
Chief Administrative Officer and Chief Financial Officer
Adam Zaeske
Chief Commercial Officer
Andrew Serafin
Chief Strategy Officer
Kumar Budur
Chief Medical Officer